Seeking Alpha

Teva launches generic Adenoscan in U.S.

  • Teva (TEVA) announces the U.S. launch of generic Adenoscan, the arrhythmias treatment marketed by Astellas Pharma (ALPMF.PK, ALPMY.PK).
  • TEVA enjoys 180 days of market exclusivity by virtue of being first to file.
  • Adenoscan has annual U.S. sales of around $65M. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs